BIT

5.00%

1.9¢ biotron limited

Thanks GY!Infinite time being taken by CROs to analyze the...

First 29 Last

Share
Profile

Follow
a2zz

675 Posts.

101

26/04/24

12:06

Post #: 73522433
Share

Originally posted by GiddyYup: ↑

Good Morning A2.

Difficult question since there are a lot of moving factors which I suspect will play out in slow motion over the next 2 months but I suspect the answer is likely to be "Yes". Here's why .....

In today's announcement they have reset expectations for results to be end of this quarter. No longer are they saying "coming weeks". CR needs to be completed before end of the quarter since money looks like running out mid July based on current burn rate.

As I wrote the other day, based on their past behavior I expect the issue price to be in the vicinity of 4.5c (Either 4 and 5 if they chose to round it off). SP will likely fall based on the fact that holders can buy new shares cheaper than on market, same as always happens. Company knows this so usually attaches options as an added incentive to pay up.

The narrative created is that you are being given a chance not only support the company to get these trials over the line and put the company into a strong financial position going into commercialization discussions but also the unwritten and obvious pull that this is a chance to get "cheap" shares and options right before the finish line. Longer term followers will find this rings some bells.

Now, if they release results early (and by early I mean only 18 months late) and the results disappoint then my answer will likely be no. But truthfully I'm not expecting to see results before the CR so I think the carrot of extra tickets in the BIT lottery will remain key to what is about to happen.

As I said to Lux yesterday, I expect most will find that they have been backed into a corner with little choice but to pay up. It will be framed as an opportunity. Some will already be stretched from the last CR having taken up extras. Some will find that they were already in as far as they were comfortable with and will be forced to make a difficult decision. Others will just throw money money at it and say "in for a penny, in for a pound". Overall however I expect them to get the money since the majority of us here are likely gamblers by nature and nobody want the undertaker to get their cheap shares.

I hope this helps.

Expand

Thanks GY!
Infinite time being taken by CROs to analyze the results has been an opportunity for them to consume time and cash, and hold a carrot to take more cash.
We did not see any cash preservation strategy by biotron as found in other compnaies.

Should an underwrite be interested given the nature of the biotron business?

Last edited by a2zz: 26/04/24

BIT Price at posting: 6.3¢ Sentiment: Buy Disclosure: Held
2 Upvote

0 Great analysis

Reply

Top Stories

BCI

BCI reaches close of funding facility for salt-first part of Mardie project

NTI

Neurotech knocked back by FDA as agency declares target condition not rare enough for special status

COD

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

CKA

Cokal upgrades infrastructure for BBM ramp-up in Indonesia

BUX

Buxton projects new graphite province discovery at WA Narryer play

Week 40 Wrap: China's nonsensical stimmy hype wanes (shocking!); HotCopper's picks; oil & inflation

WCN

White Cliff jumps 24% on 'bonanza grade' copper rock chips at Rae project, Canada

SLS

Solstice Minerals to ramp up drilling campaign at Yarri Gold Project

RCE

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

ACW

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

There are more pages in this discussion • 147 more messages in this thread...

First 29 Last

Add BIT (ASX) to my watchlist

(20min delay)
Last 1.9¢		Change -0.001(5.00%)		Mkt cap ! $17.14M

Open	High	Low	Value	Volume
1.9¢	1.9¢	1.9¢	$5.671K	298.4K

Buyers (Bids)

No.	Vol.	Price($)
3	512798	1.9¢

Sellers (Offers)

Price($)	Vol.	No.
2.0¢	1050263	5

View Market Depth

No.	Vol.	Price($)
3	512798	0.019
10	1774771	0.018
8	927388	0.017
12	3258350	0.016
7	865000	0.015

Price($)	Vol.	No.
0.020	1000263	4
0.021	555000	2
0.022	997769	4
0.023	1100772	2
0.024	153949	2

Last trade - 15.59pm 04/10/2024 (20 minute delay)

BIT (ASX) Chart

Thanks GY!Infinite time being taken by CROs to analyze the...

BCI reaches close of funding facility for salt-first part of Mardie project

Neurotech knocked back by FDA as agency declares target condition not rare enough for special status

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

Cokal upgrades infrastructure for BBM ramp-up in Indonesia

Buxton projects new graphite province discovery at WA Narryer play

Week 40 Wrap: China's nonsensical stimmy hype wanes (shocking!); HotCopper's picks; oil & inflation

White Cliff jumps 24% on 'bonanza grade' copper rock chips at Rae project, Canada

Solstice Minerals to ramp up drilling campaign at Yarri Gold Project

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Thanks GY!Infinite time being taken by CROs to analyze the...

Top Stories

BCI reaches close of funding facility for salt-first part of Mardie project

Neurotech knocked back by FDA as agency declares target condition not rare enough for special status

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

Cokal upgrades infrastructure for BBM ramp-up in Indonesia

Buxton projects new graphite province discovery at WA Narryer play

Week 40 Wrap: China's nonsensical stimmy hype wanes (shocking!); HotCopper's picks; oil & inflation

White Cliff jumps 24% on 'bonanza grade' copper rock chips at Rae project, Canada

Solstice Minerals to ramp up drilling campaign at Yarri Gold Project

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News